Diseases
Anti-Infective Peptides
Competitor Analysis
| Publication Date | January 2009 |
| Publisher | La Merie |
| Product Type | Brief |
| Pages | 41 |
| ISBN Number | not applicable |
| Product Code | LME00074 |
Price
approximately: $409 | €301
pdf immediate delivery
Order above formats by FAX
Summary
Product Description
The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of January 2009. Stages of the anti-infective peptide R&D projects range from early research to market.
Anti-Viral Peptides
Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).
Anti-Bacterial Peptides
Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram+ and gram- infections, prevention of catheter-related infections, otitis media, gingivitis and many more.
Anti-Fungal Peptides
Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more
The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Contents
- Index
- Anti-Bacterial Peptides
- Anti-Viral Peptides
- Anti-Fungal Peptides
- Corporate PTH Receptor Agonist R&D Pipelines
- About La Merie
- Corporate PTH Receptor Agonist R&D Pipelines
- Alfacell
- AM-Pharma
- Ambrilia
- Astellas Pharma
- AstraZeneca
- Cadence Pharmaceuticals
- Cubist Pharmaceuticals
- Demegen
- Digna Biotech
- Dynamic Microbials
- FusoGen Pharmaceutical
- Genaera
- Green Cross
- Helix BioMedix
- ImmuneRegen Biosciences
- ImmuPharma
- Inimed Pharmaceuticals
- Lytix Biopharma
- MacroChem
- Merck & Co.
- Migenix
- Novacta
- Novartis
- Novexel
- Novozymes
- OctoPlus
- ONI Biopharma
- OyaGen
- Pacgen
- PepTx
- Pfizer
- RecombinoGen
- Roche
- SciClone Pharmaceuticals
- Sigma-Tau
- SpiderBiotech
- Targanta
- Theravance
- Tohoku University
- Trimeris
- University of Western Ontario
- University of Wisconsin
- Viral Genetics
- Xigen
- XOMA
